Anti-angiogenic effects of biotechnological therapies in rheumatic diseases

Francesco Paolo Cantatore, Nicola Maruotti, Addolorata Corrado, Domenico Ribatti

Research output: Contribution to journalReview article


Introduction: Angiogenesis plays a key role in the pathogenesis of numerous rheumatic diseases, such as rheumatoid arthritis, psoriatic arthritis, and vasculitides. Therefore, the inhibition of pathological angiogenesis may be considered a useful therapeutical approach in these rheumatic diseases. Methods: This review article is based on a literature research about the role of biotechnological therapies in angiogenesis inhibition. Results and conclusions: Several evidences have demonstrated a role for biotechnological therapies in angiogenesis inhibition. Nevertheless, further research and clinical trials are needed to better quantify the real impact of biotechnological therapies on pathological angiogenesis.

Original languageEnglish
Pages (from-to)123-128
Number of pages6
JournalBiologics: Targets and Therapy
Publication statusPublished - Dec 14 2017



  • Abatacept
  • Anakinra
  • Angiogenesis
  • Rituximab
  • TNF-α
  • Tocilizumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Oncology
  • Gastroenterology
  • Pharmacology (medical)

Cite this